tiprankstipranks
Trending News
More News >
Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism
PremiumRatingsPromising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism
25d ago
Promising Interim Data and Accelerated Approval Pathway Drive Buy Rating for RegenXBio’s RGX-202
Premium
Ratings
Promising Interim Data and Accelerated Approval Pathway Drive Buy Rating for RegenXBio’s RGX-202
28d ago
RegenXBio: Promising Gene Therapy Developments and Strong Financial Position Support Buy Rating
Premium
Ratings
RegenXBio: Promising Gene Therapy Developments and Strong Financial Position Support Buy Rating
28d ago
Regenxbio signs strategic royalty monetization agreement for up to $250M
PremiumThe FlyRegenxbio signs strategic royalty monetization agreement for up to $250M
2M ago
REGENXBIO’s Earnings Call Highlights Strong Start to Fiscal Year
Premium
Company Announcements
REGENXBIO’s Earnings Call Highlights Strong Start to Fiscal Year
2M ago
NS Pharma announces FDA accepted BLA submission of Regenxbio for RGX-121
Premium
The Fly
NS Pharma announces FDA accepted BLA submission of Regenxbio for RGX-121
2M ago
REGENXBIO Reports Strong Q1 2025 Financial Results
PremiumCompany AnnouncementsREGENXBIO Reports Strong Q1 2025 Financial Results
2M ago
Regenxbio reports Q1 EPS 12c vs. ($1.38) last year
Premium
The Fly
Regenxbio reports Q1 EPS 12c vs. ($1.38) last year
2M ago
Controversial doctor Vinay Prasad named CBER director, STAT reports
Premium
The Fly
Controversial doctor Vinay Prasad named CBER director, STAT reports
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100